Date:3/16/2010

- (977,051) - (6) - (6) --------- --------- ------- --------- Net Income (loss) $9,316,127 $(5,077,953) $(1,261,631) $(3,301,085) ========== =========== =========== =========== Net income (loss) per common share – basic and diluted $0.17 $(0.11) $(0.02) $(0.07) ===== ====== ====== ====== Weighted average common shares outstanding – basic 54,207,761 46,930,439 54,207,761 46,930,439 Weighted average common shares outstanding – diluted 54,374,522 46,930,439 54,374,522 46,930,439 The Year Ended December 31, -------------------------------------------------------- Pro forma Pro forma Audited Audited Results Results 2009 2008 2009* 2008* ---- ---- ----- ----- Revenues $444,946 $416,912 $444,946 $416,912 --------- --------- ------- --------- Research and development (4,302,298) (11,041,930) (3,633,251)(1) (9,965,058)(1) General and administrative (4,855,582) (6,529,346) (4,615,487)(1) (5,623,029)(1) --------- --------- --------- --------- Loss from operations (9,157,880) (17,571,276) (8,248,738) (15,588,087) --------- ---------- --------- ---------- Interest income (expense), net (6,327,363) (447,626) (1,025,036)(8) (13,365)(8) Change in fair value
'/>"/>

SOURCE Cardium Therapeutics Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Related medicine technology :

1. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
4. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
5. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
6. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
7. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
8. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
9. Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers
10. Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development
11. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds